occurred in 57.1% of mortality cases, followed by sepsis/septicemia (39.3%), coagulopathies (23.8%), renal failure (19.4%) wasting syndrome/weight loss (18.4%), liver disease (16.2%) heart failure (9.7%), lymphoma (6.6%), metastatic cancer (3.3%), pulmonary circulation disorders (2.9%), and solid tumors (2.8%). Regression analyses found that increased mortality and charges were associated with each aforementioned comorbidity except wasting syndromes/weight loss. Significant (pՅ0.05) odds ratios were observed for inpatient mortality ranging from 1.17 (renal failure) to 8.06 (sepsis/septicemia) and exponentiated beta-coefficients for charges ranging from 1.03 (liver disease) to 1.33 (sepsis/septicemia). Various cancers were associated with substantially worse outcomes. CONCLUSIONS: An increased understanding of severe comorbidities in HIV/AIDS is of continued importance within hospital settings. Sepsis/septicemia and cancer is particularly associated with increased inpatient mortality and charges. 
OBJECTIVES:
Systematically review all randomized trials evaluating licensed rotavirus vaccines for efficacy and safety on diarrhoea, hospital admission, death and serious adverse events. METHODS: Electronic searches strategies were performed until October 2011. Trial eligibility, data extraction and quality assessment were performed independently by two reviewers. Dichotomous data were pooled using the risk ratio (RR) and 95% CI. GRADE was used to evaluate evidence quality. RESULTS: Forty-three RCTs including 190,551 participants were identified; 31 trials assessed RV1, and 12 RV5. In children Յ 1 year, RV1 (RRϭ0.20, 95%CI0.11 to 0.35; 7 trials, 35,004 participants) and RV5 (RRϭ0.23, 95%CI 0.08 to 0.71; 3 trials, 6953 participants) are highly efficacious against severe rotavirus diarrhoea cases and/or rotavirus diarrhea requiring hospitalization. For all-cause diarrhea, RV1 reduces severe cases by 42% (RRϭ0.58, 95% CI 0.40 -0.84; 8291 participants), and RV5 by 72% (RRϭ0.28, OBJECTIVES: MRSA-B is associated with high morbidity and cost. Guidelines recommend alternative treatment when VAN MICs are Ͼ2. DAP effectiveness in MRSA-B patients (pts) with elevated VAN MICs is an important real-world question. This analysis evaluates outcomes relevant to pts and institutions including clinical success, DAP-related length of stay (LOS), and infection-related readmission. METHODS: All pts with MRSA-B were identified in CORE 2010, a retrospective, multicenter, observational registry of staphylococcal bacteremia pts with VAN MICՆ2 mg/L per local lab. Investigators assessed pt outcome (cured, improved, failed, nonevaluable) at the end or at last contact of DAP therapy. Pt characteristics and outcomes are based on the efficacy population. All pts were included in the safety analysis. RESULTS: A total of 158 pts with MRSA-B were identified; 142 had initial VAN MICϭ2 and were evaluable for outcome: 47% male, 40% Ͼ65 years, 27% CrCl Ͻ30mL/min, 21% on dialysis, 22% treated in the ICU. Frequent concurrent infections included skin and skin structure (12%), endocarditis (9%), bone/joint (8%). Median (min,max) DAP dose and duration were 6 mg/kg (4,11) and 13.5 days (2,62), respectively. 80% (114/142) received prior antibiotics; (88% of which was VAN). Success occurred in 89% overall, with no difference between first (89% [25/ 28]) and second-line (89% [101/114]) DAP treatment. Time to clinical response ranged from 1-27 days (medianϭ2). Median (min,max) DAP-related LOS was 9 days (2,44). 21 pts (15%) were evaluated in the ER within 60 days of completing DAP therapy. Infection-related readmission occurred in 10 pts (7%). 7 pts experienced 9 AEs possibly related to DAP; 5 pts discontinued DAP due to AE. Overall mortality rate was 12%; 4 pts died within Յ7 days. CONCLUSIONS: This evaluation of realworld effectiveness demonstrates that DAP may be a useful agent for MRSA-B isolates with a VAN MICϭ2. Additional comparative effectiveness and resource utilization studies are warranted. 
PIN4 EFFICACY AND SAFETY OF THE COMBINATION TENOFOVIR (TDF)/ EMTRICITABINA (FTC) ؉ EFAVIRENZ (EFV) IN TREATMENT OF NAIVE ADULT PATIENTS WITH HIV-1 INFECTION: A SYSTEMATIC REVIEW

OBJECTIVES:
The objective was to evaluate the efficacy and safety of the combination TDF/FTCϩEFV compared to the available treatment combinations in Mexico. METHODS: We conducted a systematic review using the Cochrane guidelines of randomized clinical trials in PUBMED,EMBASE, LILACS AND ARTEMISA to compare TDF/FTCϩEFV, ABC/3TCϩEFV, ZDV/3TCϩEFV, LPV/rϩTDF/FTC and LPV/rϩABC/ 3TC in naïve adult patients with HIV-1 infection. The main outcome variables were RNA HIV-1 copies less than 50/mm3 at 48 and 96 weeks, and grade 2-4 adverse effects at 48 effects. We used a random model effects for the pooled analysis. RESULTS: We included 6 articles, 4 at 48 weeks and 2 at 96 weeks. The arms were grouped by the tree elements of HAART. The combination TDF/FTCϩEFV was the most frequently used (3 studies). At 48 and 96 weeks the pooled probabilities to have Ͻ 50 RNA copies/ml for TDF/FTCϩEFV were 0.771 (CI95% 0.711 -0.821; nϭ681) and 0.670 (CI95% 0.607 -0.727; nϭ232); ZDV/3TCϩEFV 0.704 (CI95% 0.643 -0.758; nϭ243) and 0.610(CI95% 0.546 -0.671; nϭ231); LPV/rϩABC/3TC 0.680 (CI95% 0.629 -0.727; nϭ343) and 0.600(CI95% 0.527 -0.631; nϭ343); ABC/3TCϩEFV 0.677 (CI95% 0.509 -0.809; nϭ437); and LPV/rϩTDF/FTC 0.670 (CI95% 0.619 -0.718; nϭ345) and 0.580(CI95% 0.527 -0.631; nϭ345) respectively. The adverse events rates (hypersensitivity and diarrhea) at 48 weeks were for TDF/FTCϩEFV 0.005 (CI95% 0.001 -0.036) and 0.050 (CI 95% 0.017-0.136) respectively, TDF/FTCϩEFV show fewer adverse events than compared to the other treatment regimens (LPV/rϩTDF/FTC, ABC/ 3TCϩEFV and LPV/rϩABC/3TC ). At 48 weeks the discontinuation rate for EFV ϩ ZDV/3TC was 0.91,( nϭ254) and for LPV/r ϩ TDF/FTC 0.041 (nϭ170). CONCLUSIONS: The combination TDF/FTCϩEFV is the most studied combination and it is clinically effective at 48 and 96 weeks, with good safety profile.
PIN5 SYSTEMATIC REVIEW OF INTERFERON FREE BASED REGIMENS FOR CHRONIC HEPATITIS C TREATMENT
Aggarwal S Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: Chronic Hepatitis C virus (HCV) infection is one of the silent global epidemics with significant unmet need and disease burden. One of the major limitations of current treatments is the need for 12 or 6 months of Interferon based therapy, which has tolerability and toxicity issues for many patients. During last 2-3 years several new agents have been tested in clinic, which have shown promising results as non-interferon based therapy. Goal of this study was to review the clinical efficacy and safety profile of non-interferon based therapies for HCV treatment. METHODS: We searched the MEDLINE, and abstracts from AASLD and EASL until May 2011. Studies were selected for clinical trials on direct acting agents for HCV. Primary endpoints reviewed were Sustained Viral Response (SVR). Toxicity was evaluated as secondary endpoint. Aggregated data were further analyzed to understand comparative safety and efficacy. RESULTS: Until May 2011, results of five eligible HCV clinical trials for interferon free regimens were available. Overall, treatment with combination of protease and polymerase inhibitor showed dramatic viral load reduction after 2 weeks of treatment. The combination of PSI-7977 and PSI-938 showed 93% viral clearance after 14 days (nϭ16). The combination of RG7227 and RG7128 demonstrated 5.1 log reduction in viral load in treatment naive, and 4.9 log reduction in null responder patients after 14 days of treatment. The combination of BMS-790052 and BMS 650032 showed 36.3% 24 week SVR in null responder patients. One study evaluating VX-222 and Telaprevir combination was discontinued due to viral breakthrough. Several studies are currently on-going whose data would be available in 2011-2012. CONCLUSIONS: Non-interferon based therapies have shown impressive viral load reduction in short term studies. However, more data for SVR, viral breakthrough and resistance is needed to confirm their safe use in HCV infected population. 
PIN6 EVALUATION OF THE CLINICAL AND ECONOMIC BURDEN OF THE HUMAN IMMUNODEFICIENCY VIRUS IN VETERAN PATIENTS IN THE UNITED STATES
OBJECTIVES:
To assess the clinical and economic burden of the human immunodeficiency virus (HIV) in the US veteran population. METHODS: A retrospective study including patients diagnosed with HIV between October 1, 2005 and September 30, 2010 was conducted using the Veterans Health Affairs Medical SAS Datasets. Health care resource utilization and costs were assessed in the 12-month follow-up period. Patients' demographic, clinical and discharge statuses were compared using Chi-square testing and standardized differences. Student t-tests were used for the means of continuous variables. Mortality and survival rates were calculated using the Kaplan and Meier method and the PROC LIFETEST procedure. RESULTS: Among all study patients diagnosed with HIV (nϭ29,388), mortality rates in the 12-month follow-up period were 15.79% (nϭ4,635), and 5.15% for patients under age 40, 16.25% for patients age 40 to 65, and 30.01% for patients age 65 and over. The most commonly prescribed medications were emtricitabine/tenofovir (2.39%), efavirenz (2.34%), sulfamethoxazole/trimethopri (1.88%), lamivudine/zidovudine (1.81%), lopinavir/ritonavir (1.76%), and atazanavir (1.68%). The most commonly performed laboratory tests were for sodium (3.38%), potassium (3.27%), creatinine (3.25%), chloride (3.25%), glucose quant (3.18%), and carbon dioxide content (2.94%). For patients with HIV, the average numbers of inpatient (0.48), emergency room (ER) (0.82), physician office (35.31) and outpatient visits (35.56) were calculated per patient, separately. The percentages of inpatient (24.62%), ER (35.01%), physician office (99.90%) and outpatient visits (99.93%) were also computed, which led to the following costs for inpatient ($7,828), ER ($329), physician office ($14,080) and outpatient visits ($14,450). CONCLUSIONS: This study found that emtricit-A237 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
